305 related articles for article (PubMed ID: 26807589)
21. Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
Venter WDF; Kambugu A; Chersich MF; Becker S; Hill A; Arulappan N; Moorhouse M; Majam M; Akpomiemie G; Sokhela S; Poongulali S; Feldman C; Duncombe C; Ripin DHB; Vos A; Kumarasamy N
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):224-233. PubMed ID: 30640204
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
[TBL] [Abstract][Full Text] [Related]
23. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
Jotwani V; Scherzer R; Estrella MM; Jacobson LP; Witt MD; Palella FJ; Macatangay B; Bennett M; Parikh CR; Ix JH; Shlipak MG
Am J Kidney Dis; 2016 Oct; 68(4):571-581. PubMed ID: 27287300
[TBL] [Abstract][Full Text] [Related]
24. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
25. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
Dahlin A; Wittwer M; de la Cruz M; Woo JM; Bam R; Scharen-Guivel V; Flaherty J; Ray AS; Cihlar T; Gupta SK; Giacomini KM
Pharmacogenet Genomics; 2015 Feb; 25(2):82-92. PubMed ID: 25485598
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
Noe S; Heldwein S; Jaeger H; Page M; Wolf E
Int J STD AIDS; 2019 Apr; 30(5):447-452. PubMed ID: 30630396
[TBL] [Abstract][Full Text] [Related]
27. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
[TBL] [Abstract][Full Text] [Related]
28. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Punyawudho B; Pengsuparp T
Antimicrob Agents Chemother; 2015; 59(6):3240-5. PubMed ID: 25801567
[TBL] [Abstract][Full Text] [Related]
29. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
30. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
31. Proximal tubular dysfunction related to tenofovir in people living with HIV/AIDS: a pharmacogenetic study.
Soares RCA; De Araújo PSR; Brandão LAC; Coelho AVC; Lima K; De Melo HRL
Pharmacogenet Genomics; 2022 Dec; 32(9):293-300. PubMed ID: 36256702
[TBL] [Abstract][Full Text] [Related]
32. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W
Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320
[TBL] [Abstract][Full Text] [Related]
33. ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.
Cheli S; Baldelli S; De Silvestri A; Fusi M; Minisci D; Gervasoni C; Cattaneo D; Clementi E; Meraviglia P; Montrasio C
Pharmacogenomics J; 2021 Oct; 21(5):586-593. PubMed ID: 33850298
[TBL] [Abstract][Full Text] [Related]
34. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
Mashingaidze-Mano R; Bwakura-Dangarembizi MF; Maponga CC; Morse GD; Monera-Penduka TG; Mtisi TJ; Mudzviti T; Mujuru HA
PLoS One; 2020; 15(7):e0235759. PubMed ID: 32634168
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Sukasem C; Punyawudho B
Pharmacogenomics; 2017 Nov; 18(16):1481-1490. PubMed ID: 29061086
[TBL] [Abstract][Full Text] [Related]
36. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters.
Danjuma MI; Egan D; Abubeker IY; Post F; Khoo S
Int J STD AIDS; 2018 Aug; ():956462418786562. PubMed ID: 30071797
[TBL] [Abstract][Full Text] [Related]
38. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
[TBL] [Abstract][Full Text] [Related]
39. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Winston A; McAllister J; Amin J; Cooper DA; Carr A
HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
[TBL] [Abstract][Full Text] [Related]
40. Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
Marcelin JR; Berg ML; Tan EM; Amer H; Cummins NW; Rizza SA
PLoS One; 2016; 11(2):e0149562. PubMed ID: 26872144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
